Trillium begins dosing in Phase I trial of TTI-621 for solid tumours and mycosis fungoides

Clinical stage immuno-oncology company Trillium Therapeutics has begun dosing in its second Phase I clinical trial of TTI-621 (SIRPaFc) in patients with relapsed or refractory percutaneously accessible solid tumours and mycosis fungoides.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news